Sanofi Stock Euronext Paris
Stocks
SANNV
FR0014013QA3
Pharmaceuticals
OTC Markets Traded| Market Cap | 86.01B 98.02B 81.23B 74.03B 139B 9,394B 140B 972B 377B 4,799B 368B 360B 15,425B | P/E 2026 * |
11.4x | P/E 2027 * | 9.96x |
|---|---|---|---|---|---|
| Enterprise Value | 97.47B 111B 92.06B 83.89B 157B 10,646B 158B 1,102B 427B 5,439B 417B 408B 17,480B | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | 1.86x |
| Free-Float |
88.34% | Yield 2026 * |
5.93% | Yield 2027 * | 6.26% |
Last Transcript: Sanofi
| 1 day | +6.12% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.12% | -1.27% | - | - | 98.02B | |
| +0.13% | +2.65% | +65.61% | +114.28% | 1,055B | |
| +0.20% | +0.46% | +52.60% | +69.24% | 654B | |
| -0.29% | +0.14% | +20.96% | +70.93% | 467B | |
| -0.85% | +0.98% | +41.29% | +44.38% | 348B | |
| +0.71% | +4.08% | +22.24% | +29.51% | 275B | |
| +1.23% | +0.42% | +14.57% | +12.13% | 258B | |
| +2.11% | +7.51% | +52.89% | +55.37% | 224B | |
| +0.83% | +0.55% | +35.99% | +101.70% | 187B | |
| 0.00% | -10.14% | -29.94% | -60.30% | 171B | |
| Average | +0.93% | +0.74% | +30.69% | +48.58% | 404.26B | |
| Weighted average by Cap. | +0.18% | +1.32% | +41.54% | +67.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.65B 54.3B 45B 41.01B 76.77B 5,204B 77.32B 539B 209B 2,659B 204B 199B 8,545B | 50.64B 57.71B 47.83B 43.59B 81.6B 5,532B 82.18B 572B 222B 2,826B 217B 212B 9,082B |
| Net income | 7.48B 8.52B 7.06B 6.44B 12.05B 817B 12.14B 84.52B 32.74B 417B 32B 31.31B 1,341B | 8.89B 10.13B 8.39B 7.65B 14.32B 971B 14.42B 100B 38.9B 496B 38.02B 37.2B 1,594B |
| Net Debt | 11.46B 13.06B 10.83B 9.87B 18.47B 1,252B 18.6B 130B 50.18B 640B 49.05B 47.99B 2,056B | 8.34B 9.5B 7.87B 7.17B 13.43B 910B 13.53B 94.21B 36.49B 465B 35.67B 34.9B 1,495B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
